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Methyldopa Combined with Prindolol in the
Treatment of Severe Hypertension
Y. K. SEEDAT
SUMMARY
In a clinical trial of 30 patients suffering from severe
hypertension (diastolic blood pressure <\qove 130 mmHg)
the combination of methyldopa and prindolol produced a
satisfactory drop in blood pressure; a further 2 patients
were satisfactorily controlled with the addition of furo-
semide 40 mg daily. Side-effects were few, and this trial
was characterised by the absence of postural hypoten-
sion; this combination did not enhance central nervous
system side-effects. A synergistic effect between methyl-
dopa and ,a-adrenergic blocking agents as regards their
hypotensive effect may exist, and the combination may
be a better alternative to use than sympatholytic agents
such as guanethidine or bethanidine sulphate in the treat-
ment of severe hypertension.
S. Afr. Med. J., 48, 1608 (1974).
One of the problems confronting a clinician in the treat-
ment of hypertension is that intolerable side-effects may
make the patient feel even worse. Bethanidine sulphate or
guanethidine act by depleting the peripheral arterioles of
noradrenaline and cause side-effects such as impotence,
postural hypotension, giddiness or diarrhoea.' Beta-
adrenergic blocking agents produce no postural hypoten-
sion or sexual disturbance, but have been found to be of
value mainly in mild to moderate hypertension.'" More-
over, it is probably unwise to exceed the anti-anginal dose
in the treatment of hypertension, viz. propranolol 320 mg
daily or prindolol 45 mg daily, because of the cost of
therapy and because a further drop in blood pressure
(BP) would probably be relatively small.' This clinical
trial was thus initiated to determine if methyldopa (Aldo-
met), a hypotensive agent which produces little postural
hypotension, could be used effectively with prindolol
(Visken) in the treatment of severe hypertension.
PATIENTS AND METHODS
Thirty patients suffering from severe hypertension (initial
diastolic BP of 130 mmHg or above) were selected for
this trial. Patients who were previously on guanethidine
or bethanidine sulphate were taken off their therapy, and
once the original diastolic BP was attained (usually be-
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tween 5 - 7 days) they were put on methyldopa. All patients
were initially put on methyldopa I g daily (divided dose
of 500 mg every 12 hours) for a period of 2 weeks, because
methyldopa produces a hypotensive effect quickly, where-
as ,a-adrenergic blocking agents may have a delayed effect.'
After 2 weeks prindolol (Visken) 5 mg twice daily was
added and the dose increased at weekly intervals to a
dose that produced a diastolic BP of less than 100 mmHg.
Patients suffering from overt manifestations of cardiac
failure or bronchial asthma were excluded from the trial.
There were 17 Black and 13 Indian patients in this clinical
trial-16 females and 14 males.
RESULTS
At the end of the 3-month trial 28 of the 30 patients were
effectively controlled with methyldopa 1 g daily and prin-
dolol in a variable dose. In the 2 patients in whom a
diastolic BP of 100 mmHg was not attained, furosemide
40 mg daily produced the required drop in BP. Tolerance
was defined as a state in which an increase in the dosage
of prindolol became neCe6sary because of a rise in the
diastolic BP after a level of 100 mmHg or less had been
obtained, and was not seen in any of the patients.
The initial mean arterial pressure (MAP) was 158,3. On
therapy with methyldopa the MAP was 138,7. The addi-
tion of prindolol produced a MAP of 111,5 (Table I). The
median dose of prindolol was 26,3 mg. The mean blood
urea before therapy was 44,8 mg/l00 m1 and after therapy
it was 48,9 mg/lOO ml (Table Il). The pulse rate before
therapy was 76/minute, on therapy with methyldopa 74/
minute, and with the addition of prindolol 72/minute
(Table Ill). Side-effects of previous hypotensive therapy
included drowsiness, postural hypotension, impotence and
diarrhoea. A feature of the combination of methyldopa
and prindolol was the absence of postural hypotension as
a side-effect, and the presence of impotence in only one
patient on methyldopa. There did not appear to be any
enhancement of central nervous system side-effects when
prindolol was combined with methyldopa,
DISCUSSION
This clinical trial was undertaken to determine if the
combination of methyldopa and prindolol is effective in
the treatment of severe hypertension and without side-
effects, such as postural hypotension, which may occur
with hypotensive agents like guanethidine or bethanidine
sulphate. A previous trial has shown that patients who
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TABLE 11. BLOOD UREA BEFORE AND AFTER THERAPY
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TABLE Ill. PULSE RATE BEFORE AND AFTER THERAPY
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did not respond to prindolol were more likely to be
patients who had an initial diastolic BP above 130 mmHg.·
While isolated reports of the combination of methyldopa
and prindolol have appeared,'" there was no clear evidence
of the value of the combination of methyldopa and
f3-adrenergic blocking agents in the treatment of hyperten-
sion. Previous work on propranolol' has shown that: (a)
its full hypotensive effect may take several weeks; (b) the
required hypotensive dose of 760 mg was usually greater
than the effective anti-anginal dose of 320 mg daily, with
a wide fluctuation in dose requirement; and (c) it did not
produce postural or postexercise hypotension. Methyldopa
also produces little postural hypotension,'· and it was
decided to use the drug in combination with prindolol to
determine: (a) if there was a synergistic hypotensive effect;
(b) if side-effects of other hypotensive agents could be
obviated, especially postural hypotension and sexual dis-
turbance.
Prindolol, a newer f3-adrenergic blocking agent, has two
important advantages over propranolol: increased dose-
for-dose potency and fewer side-effects, particularly a
lesser effect on the pulse rate.' Animal experiments have
shown that prindolol has less of the quinidine effect seen
with propranolol.ll There is conflicting evidence as to the
mode of action of prindolol, but it seems that there may
be an effect mediated through the central nervous system
because of evidence in humans of mental depression,
8
insomnia and vivid dreams as side-effects." There is no
explanation for the action of methyldopa. The theory of
the false 'neurotransmitter' has been suggested, and it is
believed that the decarboxylation of a-methyldopa in the
central nervous system is a prerequisite for its hypotensive
effect.13
This clinical trial showed that methyldopa in a fixed
dose of I g daily, combined with prindolol in a median
dose of 26 mg daily, produced a satisfactory drop in
BP. A further 2 patients were effectively controlled when
furosemide 40 mg daily was added. Side-effects occurred
in 7 patients on methyldopa and in 4 of them drowsiness
disappeared after a week. Five patients developed side-
effects on prindolol therapy. There did not appear to be
any potentiation of central nervous system side-effects, in
spite of both these drugs having that potential. No patient
developed dizziness or postural hypotension on the com-
bination of methyldopa and prindolol, unlike 5 patients
who experienced this side-effect on bethanidine sulphate
and 4 patients on guanethidine therapy. A feature of
f3-adrenergic blocking agents is the absence of any impo-
tence or failure of ejaculation in the male-no patient
developed these side-effects on prindolol and only 1
patient developed impotence on methyldopa. There was
little effect of the combination of methyldopa and prin-
dolol on the pulse rate, and the initial pulse rate dropped
from 76 to 72/minute after therapy. The difference be-
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tween recumbent and standing blood pressures was 5
mmHg. The mean rise in blood urea after therapy was
only 4 mg/ 100 ml. Ten patients suffered from renal hyper-
tension, and there was no deleterious effect on therapy.
This clinical trial showed that the combination of
methyldopa and prindolol is of value in the treatment of
severe hypertension. Previous work has shown the value
of combining propranolol with hydralazine,'· prindolol with
a diuretic' or hydralazine: It is possible that the combi-
nation of methyldopa with the newer ,a-adrenergic blocking
agents may be a suitable alternative to the sympatholitic
agents in the treatment of severe hypertension.
I wish to thank Sandoz Pharmaceuticals (SA) Ltd for their
support.
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A Double-Blind Gastroscopic Study of a
Bismuth-Peptide Complex in Gastric Ulceration
M. G. MOSHAL
SUMMARY
Forty courses of treatment with bicitropeptide (BCP)
were administered to 30 patients with gastric ulcers, in
a double-blind crossover trial. Healing was judged gastro-
scopically after 4 weeks, at which time 79% of ulcers had
healed on BCP and 35% on placebo (P<O,Ol). There
were no side-effects. Bicitropeptide is a bismuth-protein
complex, active at a pH of less than 4. A protective
'protein-bismuth complex' layer is said to be formed over
the ulcer.
S. A/I'. Med. l., 48, 1610 (1974).
At present the only treatments that have been shown in
controlled trials to affect the rate of healing of gastric
ulcers are carbenoxolone sodium.' bed rest and cessation
of smoking.' The drug carbenoxolone sodium causes
the advent of side-effect, in a small but significant number
of patients, including salt and water retention. Symptoms
may be relieved by antacids," but these appear not to
affect the rate of healing. In this trial, the effect of a
bismuth-protein complex (bicitropeptide (BCP); Med-Nim)
active at the range of acid pH (below 4,0) usually present
in the stomach, has been tested in the treatment of gastric
ulceration.
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METHODS
Thirty patients with benign chronic gastric ulceration seen
on endoscopy were studied. Only patients with solitary
ulcers on the lesser curve of the stomach in the neigh-
bourhood of the angulus were studied. Each patient had
a pretreatment barium meal, gastric acid output measured
after pentagastrin: in the test modified after Kay," and
a gastroscopy. The gastroscope employed was the side-
view Olympus GF type B, which has an automatic 16-mm
camera. All patients were ambulant and were given
treatment with BCP or placebo in a double-blind fashion
at a dose of 10 ml in 30 ml of water 4 times daily, half
an hour before meals and on retiring at night, for 4
weeks. Crossover was effected if symptoms had not abated
within 2 weeks. Clinical assessment was made every 2
weeks, and gastroscopic assessment was made after 4
weeks of treatment. No patient was admitted to the trial
if there was a complication such as haematemesis or
pyloric obstruction, or if there was coexisting duodenal
ulceration. Patients were advised to avoid only those
foods which appeared to produce symptoms. Smoking was
not discussed, no sedatives or other drugs were given, and
no change in resting habits was advised.
RESULTS
Forty courses of treatment were given to the 30 patients
(Table I). Ten patients received crossover therapy (7 of
